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Abstract
Ablative hyperthermia (> 55 °C) has been used as a stand-alone treatment for accessible solid tumors 
not amenable to surgery, whereas mild hyperthermia (40–45 °C) has been shown e!ective as an adjuvant 
for both radiotherapy and chemotherapy. An optimal mild hyperthermia treatment is noninvasive and 
spatially accurate, with precise and homogeneous heating limited to the target region and with reduced 
probability of unwanted thermal or mechanical bioe!ects (tissue damage, vascular shuto!).  High-inten-
sity focused ultrasound (HIFU) can noninvasively heat solid tumors deep within the human body. Mag-
netic resonance imaging (MRI) is ideal for HIFU treatment planning and monitoring in real time due to 
its superior so"-tissue contrast, high spatial imaging resolution, and the ability to measure temperature 
changes. #e combination of HIFU therapy and MRI monitoring is called magnetic resonance-guided 
high-intensity focused ultrasound (MR-HIFU).  
Low temperature-sensitive liposomes (LTSLs) release their drug cargo in response to heat (> 40 °C) and 
may improve drug delivery to solid tumors when combined with mild hyperthermia. MR-HIFU pro-
vides a way to image and control content release from imageable low-temperature sensitive liposomes 
(iLTSLs). #is ability may enable spatiotemporal control over drug delivery — a concept known as drug 
dose painting. In this paradigm, the treating physician prescribes a desired drug dose and spatial distri-
bution of drug to be delivered, and an MR-HIFU system manipulates heat in the target region to achieve 
the desired drug dose. 
#e objectives of this dissertation were to develop and implement a clinically relevant volumetric mild 
hyperthermia heating algorithm, to implement and characterize di!erent sonication approaches (mul-
tiple foci vs. single focus), and to evaluate the ability to monitor and control heating in real time with 
MR-HIFU. In addition, the ability of MR-HIFU to induce the release of a clinical-grade cancer drug 
encapsulated in LTSLs was investigated, and the potential of MR-HIFU mediated mild hyperthermia for 
clinical translation as an image-guided drug delivery method was explored. Finally, drug and contrast 
agent release of iLTSLs as well as the ability of MR-HIFU to induce and monitor the content release 
were examined, and a computational model that simulates MR-HIFU tissue heating and the resulting 
hyperthermia-mediated drug delivery was validated.
#e developed MR-HIFU mild hyperthermia heating algorithm produced accurate and homogeneous 
heating within the targeted region in vitro and in vivo. #e combination of a multifoci sonication ap-
proach and the mild hyperthermia heating algorithm resulted in accurate and precise heating within the 
targeted region with signi$cantly lower acoustic pressures. Heating was more spatially con$ned in the 
beam path direction compared to the use of single focus sonication method. #e reduction in acoustic 
pressure and improvement in spatial control suggest that multifoci heating is a useful tool in MR-HIFU 
mediated mild hyperthermia applications for clinical oncology. 
Using the mild hyperthermia heating algorithm, LTSL + MR-HIFU resulted in significantly higher tu-
mor drug concentrations compared to free drug and LTSL alone. #is technique has potential for clini-
cal translation as an image-guided method to deliver drug to a solid tumor. MR-HIFU also enabled 
real-time monitoring and control of iLTSL content release. Finally, computational models can predict 
temperature distribution and delivered drug concentration resulting from combining MR-HIFU with 
LTSLs, and may allow quantitative in silico comparison of di!erent MR-HIFU heating algorithms as well 
as facilitate therapy planning for this drug delivery technique.
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1 Introduction
1.1  Cancer therapies and mild hyperthermia
Cancer is a term used for diseases in which anomalous cells divide and grow uncontrollably, possibly 
resulting in invasion of other tissues. 1, 2 !erapies for cancer can be roughly divided into "ve categories: 
surgery, chemotherapy, radiotherapy, transplantation, and other treatment methods, which include 
angiogenesis inhibitors, photodynamic therapy, cancer vaccines, gene therapy, and hyperthermia. 2 !e 
choice of cancer therapy depends on the location and type of the tumor, the stage of the disease, as well 
as on the general well-being of the patient. 2
Mild hyperthermia, i.e., exposing tissue to temperatures slightly above normal body temperature, is a 
therapeutic technique that is used as an adjuvant or neo-adjuvant therapy in combination with other 
forms of cancer therapy such as radiotherapy and chemotherapy. 3-5 In contrast, ablative hyperthermia is 
intended to directly produce substantial cell death at temperatures commonly greater than 55 °C. 6 
!e goal of mild hyperthermia therapy is to obtain temperatures of 40–45 °C within the target tissue for 
time periods up to one hour. 3, 4 Hyperthermia treatments may result in both physiological (e.g., perfusion) 
and cellular (e.g., gene expression) changes that improve therapeutic e$ectiveness of chemotherapy and 
radiotherapy. 3 For example, mild hyperthermia may make cancer cells more sensitive to radiation or 
directly injure cancer cells, as well as enhance the e$ects of some cancer drugs. 3 
A number of clinical trials have studied mild hyperthermia in combination with radiotherapy and/or 
chemotherapy. !ese studies have focused on treatment of many types of cancer, showing that addition 
of mild hyperthermia can help provide palliative relief, as well as augment tumor response, local control, 
and survival. 3, 4, 7-9
1.2  Mild hyperthermia mediated drug delivery
Current cancer therapies utilizing chemotherapeutic agents usually rely on systemic delivery with limited 
tumor specificity, and consequently may result in adverse side e$ects in healthy tissues and insufficient 
drug delivery to the target tumor. 10-12 In order to reduce systemic toxicity and improve overall e%cacy, 
hyperthermia has been recently used in combination with temperature-responsive and non-temperature-
responsive drug delivery systems (DDS). 13 
For non-temperature-responsive DDS, mild hyperthermia has been shown to assist drug delivery with 
stealth liposomes by increasing vascular permeability, resulting in enhanced drug levels in solid tumors, 
14, 15 and may also increase the sensitivity of cancer cells to chemotherapeutics. 13 When hyperthermia 
is combined with temperature-responsive DDS, the heat may also be used as a trigger to initiate drug 
release. Temperature responsive DDS include polymers, 16 biopolymers, 17 micelles, 18 and liposomes. 19 
One of the most promising temperature-responsive DDS are temperature sensitive liposomes (TSLs) 
that release their contents in response to temperatures greater than the melting temperature of the lipid 
formulation. 19, 20 Encapsulation of a chemotherapeutic agent into liposomes has the potential to reduce 
systemic toxicity and enhance drug delivery compared with free drug. 
In recent times, low temperature sensitive liposomes (LTSLs) have been developed. 21, 22 !ese liposomes 
rapidly release the encapsulated cancer drug (e.g., doxorubicin) at mild hyperthermia (40–42 °C). 23-25 
Studies combining LTSLs with local, mild hyperthermia have demonstrated significant tumor volume 
reduction in mouse tumor models compared with conventional free drug or non-thermally sensitive 
liposome therapies. 21, 22, 26, 27 
13
Intra- and inter-patient spatial variability in tumor microenvironment may impact both the heating 
pattern and delivery of drugs. 28, 29 To accommodate this variability, mild hyperthermia treatment may 
be adjusted for optimal drug delivery by using a control algorithm. !erefore, in addition to temperature 
monitoring, direct imaging of drug delivery (or an appropriate substitute, such as release of a contrast 
agent from LTSLs) may improve real-time control of delivery or help guide future interventions. A 
suitable surrogate for quanti"cation of drug delivery may be provided by imaging contrast agent release 
from liposomes co-loaded with a drug and a contrast agent. 30
Contrast agents have been encapsulated in liposome interior compartment 31 as well as conjugated to 
their membrane, 32 or both. 33  LTSLs that release contrast agent from their interior have been used to 
monitor release in vivo, and such liposomes have demonstrated promising correlations of imaging with 
both drug delivery 34 and therapeutic e#cacy. 30
1.3  Magnetic resonance-guided high-intensity focused ultrasound 
Several methods for providing local, mild hyperthermia have been studied using techniques that 
deliver energy to a small volume, such as a tumor. 3, 7-9 Traditional hyperthermia applicators include 
radiofrequency, 35, 36 microwave, 37 hot water baths, 38 lasers, 39 and magnetic $uids. 40, 41 Despite some 
promising results, these methods su%er from drawbacks such as highly invasive nature of applicators, 
limited and super"cial heating, formation of hot spots, inaccurate or spatially uneven heating, inability to 
achieve mild hyperthermic temperatures (40–45 °C), and lack of spatiotemporal temperature feedback 
control. 3
High-intensity focused ultrasound (HIFU) utilizes tightly focused ultrasonic waves, leading to absorption 
of energy and rapid, highly localized temperature elevations at the target. HIFU represents a noninvasive 
alternative to more widely used hyperthermia applicators. Application of HIFU can result in both thermal 
and non-thermal (o&en known as mechanical) bioe%ects, both of which arise from a complex interaction 
of propagating ultrasound waves with tissue. 42-44  Importantly, HIFU bioe%ects can be manipulated and/
or controlled by adjusting device output power, ultrasound frequency, duty cycle, sonication duration, 
and focal spot characteristics.
Although focused ultrasound was suggested for localized hyperthermia and noninvasive surgery as early 
as in the 1940s, 45 the lack of suitable image guidance and temperature control techniques prevented 
it from gaining widespread clinical adoption. 46 Due to its superior so&-tissue contrast, high spatial 
image resolution, and the ability to monitor temperature changes, magnetic resonance imaging (MRI) is 
uniquely quali"ed to provide both HIFU treatment planning as well as real-time monitoring of therapy. 
!e combination of HIFU therapy and MRI monitoring is called magnetic resonance-guided high-
intensity focused ultrasound (MR-HIFU). Temperature monitoring with MRI is commonly achieved 
using the water proton resonance frequency shi& (PRFS) method, 47 which relies on the linear dependence 
of PRFS on temperature change. In the mild hyperthermic range, this linear relationship is valid in all 
non-adipose tissues. 48 !e PRFS method has been used to provide accurate and real-time thermometry 
free of interference from HIFU. 48-53 
To date, clinical MR-HIFU has been mostly used for the ablation of symptomatic uterine leiomyomata, 
50, 52, 54-56 which are common benign smooth-muscle tumors located within the uterus. MR-HIFU also 
shows promise for oncology applications, and it has been under investigation for the treatment of benign 
breast "broadenomas, 57 malignant breast  carcinoma, 58, 59  prostate cancer, 60, 61 palliative treatment 
of painful osseous metastases, 62-64 and for the ablation of brain tumors. 65, 66 In addition, MR-HIFU is 
currently under research for the treatment of neurological disorders, including epilepsy, essential tremor, 
neuropathic pain, and Parkinson’s disease. 67-69
Developments in both ultrasound applicators and MRI-based temperature monitoring and control 
methods 48, 51, 70-74 have made MR-HIFU mediated mild hyperthermia an attractive option as a noninvasive 
hyperthermia therapy modality, especially in combination with drug delivery. 
Introduction
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1.4  Feedback controlled mild hyperthermia and drug delivery using   
 magnetic resonance-guided high-intensity focused ultrasound
!e e"cacy of a mild hyperthermia treatment is associated with the temperatures achieved during 
the treatment, duration of treatment, as well as cell and tissue characteristics. 3, 7, 75 An optimal mild 
hyperthermia treatment is spatially accurate, with precise and homogeneous heating limited to the target 
region and with low likelihood of unwanted thermal or mechanical bioe#ects (direct tissue damage, 
vascular shuto#). !e ideal temperature for most mild hyperthermia applications is 40–45 °C (T < 40 °C 
causes limited e#ect, T > 45 °C may shut down tissue perfusion 3, 76), and may require durations of 30–60 
min, 76 placing strict and challenging requirements on both the hyperthermia applicator and delivery 
approaches.
Phased-array ultrasound transducers in combination with suitable driving electronics make the 
creation of di#erent focal patterns possible by enabling fast temporal displacement of the focus or the 
generation of multiple foci, thus signi$cantly increasing the heated volume. 51, 77-79 To ensure that the 
desired temperature is reached but not exceeded in the target volume, the temperature of the tumor and 
surrounding tissue must be monitored and controlled throughout a mild hyperthermia treatment. MRI 
thermometry can be utilized to perform either operator-adjustable or automated feedback control of the 
treatment  in order to improve temperature accuracy and uniformity, as well as patient safety. 23, 73, 80-83
1.5  Context of dissertation
!e work performed for this dissertation was part of a collective e#ort to develop, characterize, and validate 
methods and materials for safe, targeted, and noninvasive MR-HIFU mediated mild hyperthermia and 
drug delivery therapies. 
Locally targeted, image-guided mild hyperthermia, as well as drug delivery assisted by mild hyperthermia 
are clinically attractive and potentially useful strategies for enhancing cancer therapies and augmenting 
delivery of drugs to solid tumors. However, for these strategies to realize their full potential in the clinic, 
a hyperthermia applicator must be able to provide accurate and homogenous heating in a target volume. 
In this dissertation work, novel methods for MR-HIFU mediated mild hyperthermia and drug delivery 
have been developed and characterized for use with a clinical MR-HIFU system. !e key results of the 
related research and the relevant scienti$c background are portrayed in this dissertation. !is research 
is presented in publications I-IV.
A variety of factors, including drug delivery system, drug characteristics, as well as physiological, 
biological, and biophysical parameters, a#ect hyperthermia-mediated drug delivery from LTSLs. 
Computer simulations may provide a means to e"ciently study the e#ects of these parameters. Other 
bene$ts o#ered by computer simulations include facilitating detailed examination of heating algorithms 
and optimal drug delivery strategies. !is dissertation also describes evaluation of a computational 
model that simulates tissue heating with MR-HIFU as well as the resulting mild hyperthermia assisted 
drug delivery from LTSLs. !is research is presented in publication V. 
Finally, the use of MR-HIFU for the ablation of symptomatic uterine leiomyomata is presented in 
publication VI. !is publication showcases that combining HIFU therapy with novel MRI-based 
treatment monitoring and control is not only feasible, but already in clinical use with impressive targeting 
accuracy and an acceptable treatment safety pro$le. 
!e overview part of this dissertation includes three chapters focusing on MR-HIFU mediated mild 
hyperthermia and drug delivery. Tissue e#ects of mild hyperthermia and its use in cancer treatments, as 
well as mild hyperthermia mediated drug delivery, are presented in Chapter 2. !e basics of therapeutic 
ultrasound, interaction of HIFU with tissue, as well as methods for delivering acoustic energy using 
di#erent sonication strategies for HIFU are described in Chapter 3. Means for MRI-based treatment 
planning, temperature monitoring, and therapy assessment are described in Chapter 4. 
Chapter 1
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Furthermore, the objectives of this dissertation work are outlined below and the ful!llment of these 
objectives is discussed in Chapter 5. Finally, key results of the six publications are brie"y summarized in 
Chapter 6. 
Objectives
1. Develop and implement a clinically relevant volumetric mild hyperthermia heating algorithm 
and evaluate its ability to monitor and control heating in real time using a clinical MR-HIFU 
system. (I)
2. Implement and characterize a multifoci sonication approach in combination with the mild 
hyperthermia heating algorithm developed under objective 1, and compare it to the more 
conventional method of electronically sweeping a single focus. (II)
3. Investigate the ability of MR-HIFU to induce the release of a clinical-grade cancer drug 
encapsulated in LTSLs, and explore the potential of MR-HIFU mediated mild hyperthermia 
for clinical translation as an image-guided drug delivery method. (III)
4. Characterize the drug and contrast agent release of iLTSLs, and investigate the ability of MR-
HIFU to induce and monitor the content release. (IV)
5. Validate a computational model that simulates MR-HIFU mediated tissue heating and the 
resulting mild hyperthermia assisted drug delivery from LTSLs. (V)
In addition, the objective of publication VI was to show that MR-HIFU therapy for the ablation of 
symptomatic uterine leiomyomata is not only feasible, but already in clinical use with impressive targeting 
accuracy and an acceptable treatment safety pro!le. 
Introduction
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2  Mild hyperthermia therapy and mild 
hyperthermia mediated drug delivery
2.1  Mild hyperthermia therapy
Mild hyperthermia is a therapeutic technique, in which cancerous tissue is heated above the body 
temperature (40–45 °C for up to 1 hour) in order to induce a physiological or biological e!ect. 3, 
4 Usually, the goal of mild hyperthermia is to improve the therapeutic e!ectiveness of chemotherapy 
or radiotherapy, and it is not typically intended to directly produce substantial cell death. In contrast, 
ablative hyperthermia commonly achieves temperatures greater than 55 °C, but for shorter durations of 
20 s to 15 min, 6 with a primary goal of ensuring cancer cell death.
"e bene#cial e!ects of mild hyperthermia lie in its ability to improve the e!ectiveness of other 
treatments by modifying both physiology and biology of cancer. 3, 8, 9 Mild hyperthermia may provide 
improved tissue perfusion and oxygenation, 3 inhibit homologous recombination, 84 improve delivery of 
chemotherapy and potentiate its cytotoxic e!ects, 3 as well as augment immune response. 85 Culmination 
of these e!ects has promising potential to improve outcomes for cancer patients who receive radio- and/
or chemotherapy.
2.2  Delivery methods for mild hyperthermia
Delivery methods include local, regional, and whole-body mild hyperthermia. 5, 7, 75 Whole-body mild 
hyperthermia has been investigated as a treatment for metastatic  cancer that has spread throughout 
the body. Techniques include infrared hyperthermia domes, placing the patient in a very hot room, 
or wrapping the patient in hot, wet blankets. 5, 7 "e application of whole-body mild hyperthermia is 
accompanied with a wider range of toxic side e!ects than other mild hyperthermia modalities. 75
Regional mild hyperthermia may be applied with a variety of approaches to selectively heat volumes 
of tissue with variable size and morphology, such as a tumor and surrounding tissue, a body cavity, 
organ, or an entire limb. For example, regional perfusion techniques can be used to treat cancers in the 
extremities (e.g., melanoma) or cancer in some organs, such as in the liver or lung. In these procedures, 
the target limb or organ is perfused with the patient’s own blood that has been diverted and continuously 
circulated through a heating apparatus. 7, 75
In  local hyperthermia, heat is applied to a small volume using di!erent types of applicators, such as 
radiofrequency, 35, 36 microwave, 37 laser, 39 and ultrasound. 86, 87 "e choice of heating method for local 
mild hyperthermia is dictated largely by the tumor location. External approaches are typically used to 
treat tumors that are in or just below the skin. Endocavitary methods are used to treat tumors within or 
near body cavities, such as the esophagus or rectum. Interstitial techniques are used to treat tumors deep 
within the body, such as brain tumors. 3, 7, 9
What all mild hyperthermia modalities have in common is that they are typically used to improve the 
therapeutic e!ectiveness when used as an adjuvant or neo-adjuvant therapy, and not intended to replace 
any of the established oncological treatment modalities. "ere are a number of technological challenges 
that make mild hyperthermia therapy complicated and that have barred mild hyperthermia from 
becoming a more widely used treatment option in clinical practice. "ese challenges include applicators 
that are hard to use or control, the ability to achieve a uniform temperature in a tumor, and the ability 
to precisely monitor temperature both within the tumor and in the surrounding tissue. Applicators and 
methodology to deliver uniform levels of thermal energy, as well as devices to monitor and control the 
total amount of delivered energy, are therefore desirable. 
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2.3  Tissue effects of mild hyperthermia
Exposure to hyperthermic temperatures has been shown to damage DNA, RNA, proteins, nucleoproteins, 
chromosomes, lipids, nucleoli, membranes, lysosomes, microtubules, as well as a large variety of synthetic 
pathways and metabolic functions within the cell. 3, 75, 88 !us, hyperthermia a"ects practically all cell 
structures and functions. 
In more detail, mild hyperthermia has been shown to play a role in changing the stability and #uidity 
of cell membranes, 89, 90 altering cell shape, 5, 91 inducing apoptosis, 92 impairing protein synthesis, 5, 
93  denaturing proteins, 94, 95 inducing heat-shock protein synthesis, 95, 96 as well as in decreasing RNA/
DNA synthesis and  inhibiting repair enzymes. 5, 93, 97 Furthermore, mild hyperthermia may a"ect drug 
distribution by altering tumor blood #ow 5, 98, 99 or by increasing the enhanced permeability and retention 
(EPR) e"ect. 10, 14, 100-102
!ese e"ects may also lead to altered interactions between heat and drugs. For example, mild hyperthermia 
may a"ect pharmacodynamics by accelerating the primary mode of action of cancer therapies (e.g., DNA-
strand breaks, protein damage), or by other means, such as increasing intracellular drug concentration 
through membrane and protein damage. 75 A thorough review on the cellular and molecular e"ectors of 
mild hyperthermia as well as on the interactions between heat and drugs has been previously published 
by Hildebrandt et al. 75
2.4  Mild hyperthermia in cancer treatments, and the clinical  
 effectiveness of mild hyperthermia
A number of clinical trials have examined the safety and e$cacy of mild hyperthermia in combination 
with radiotherapy and/or chemotherapy. 3, 7, 75 !ese studies have focused on the treatment of many types 
of cancer, including sarcoma, melanoma, cancers of the head and neck, brain, lung, esophagus, breast, 
bladder, rectum, liver, appendix, cervix, and peritoneal lining. 3, 4, 7-9, 75 Many of these trials have shown 
a signi&cant reduction in tumor size when mild hyperthermia is combined with other treatments. 3, 
7, 8 !ese findings strongly suggest the clinical e"ectiveness of hyperthermia, 4, 103-108 and as such, the 
principal argument for the use of mild hyperthermia is its proven bene&t in the scope of randomized 
clinical trials. 
Radiotherapy uses high-energy radiation to kill cancer cells by damaging their DNA, resulting in 
reduction of tumor size. 109 X-rays, gamma rays, and charged particles are common types of radiation 
used in cancer treatments. Radiation may be delivered by a machine outside the body, 109 or it may arise 
from radioactive material placed in the body near tumor cells or injected into the bloodstream. 110 
An important observation based on both in vitro and in vivo studies on thermal therapies is that mild 
hyperthermia and radiation provide complementary e"ects and act in a synergistic way, signi&cantly 
increasing tumor cell death over levels achieved with radiation alone. 3, 75 !is mild hyperthermia-
mediated thermal radiosensitization (thermoradiosensitization) appears most pronounced for cells in 
synthesis-phase (DNA replication phase) of the cell cycle. !ese cells are usually less a"ected by radiation 
alone, but are the most sensitive to hyperthermia. 111, 112 However, the greatest impact of mild hyperthermia 
is likely on cells that have been deprived of oxygen. A growing tumor rapidly outgrows its blood supply, 
leaving regions in the tumor with signi&cantly lower oxygen concentration compared to healthy tissue. 
!is condition is called tumor hypoxia. Hypoxic tumor cells may be resistant to radiotherapy and 
chemotherapy, 113 but they can be made more amenable to treatment if delivery of oxygen is improved. 
!e documented ability of mild hyperthermia to improve tumor oxygenation 114 may account for its 
enhancement of radio- and chemo-sensitization. 115   
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Improved response and survival rates have been observed in patients treated with mild hyperthermia 
and radiotherapy compared with radiotherapy alone in multiple phase III trials. 116-122 Despite the 
inhomogeneity of achieved temperature distribution, the use of local and/or regional mild hyperthermia 
techniques indicated a significant correlation between thermal dose and clinical outcome in some of 
these trials. 105, 123, 124 In summary, data from both pre-clinical and clinical studies indicate that therapeutic 
outcomes may be improved by using the combination of mild hyperthermia and radiotherapy. 
Chemotherapy is a type of cancer treatment that uses drugs to destroy cancer cells. Chemotherapy 
works by stopping or slowing the progression of cancer cells, which typically grow and divide rapidly. 
2 However, chemotherapy targets all rapidly dividing cells — normal cells and cancer cells alike.  "us, 
chemotherapy can harm healthy cells that divide quickly, e.g., cells in intestinal lining, bone marrow, or 
in hair follicles, causing unwanted side e#ects such as alopecia and neutropenia. 2, 125, 126
Similarly to thermoradiosensitization, mild hyperthermia may also enhance the e$cacy of cytotoxic 
antineoplastic drugs (thermochemosensitization). 75 Several chemotherapeutic agents have been shown 
to provide synergistic bene%ts with mild hyperthermia. "ese agents include cisplatin, melphalan, 
cyclophosphamide, nitrogen mustards, anthracyclines, nitrosoureas, blyeomycin, mitomycin C, and 
hypoxic cell sensitizers. 3, 75 Mechanisms for this synergistic behavior may include increased cellular uptake, 
increased oxygen radical production, as well as increased DNA damage and inhibition of repair. 3, 5, 98, 99 
Furthermore, hypoxia and tissue acidity (pH) may also signi%cantly a#ect the thermochemotherapeutic 
response, 127-129 as these adverse aspects of the tumor microenvironment are thought to be prevalent in 
areas of inadequate or ine$cient vascular supply and may signify poor drug delivery. 130, 131 In contrary 
to hyperthermic radiotherapy, however, only few comparative trials have been completed to date where 
hyperthermia was applied as an adjunct to chemotherapy. 132-134
2.5  Mild hyperthermia mediated drug and contrast agent delivery
Conventional chemotherapy usually relies on systemic drug delivery with limited speci%city for tumor 
tissue, and therefore may result in dose-limiting toxicity, adverse side e#ects, and in reduced therapeutic 
e$cacy. "is scenario may be improved with the use of drug delivery systems (DDS) that selectively 
deliver chemotherapeutics to a tumor in an e#ort to reduce systemic toxicity and improve overall e$cacy, 
consequently resulting in a larger therapeutic window. 10-12 DDS can be designed to improve both the 
pharmacological and therapeutic properties of certain drugs. A number of DDS have been developed, 
including micellic, liposomal, polymeric, biopolymeric, and monoclonal antibody-directed delivery. 
12, 16-19 In particular, development of liposomes, which are arti%cially-prepared vesicles composed of a 
lipid bilayer, has resulted in a number of FDA-approved formulations for clinical use. 135 Encapsulation 
of a chemotherapeutic agent into liposomes may reduce systemic toxicity and enhance drug delivery 
compared with free drug. 12, 136, 137
Liposomes can target the tumor either passively based on factors such as particle size and surface 
properties, or actively due to a speci%c a$nity, activation, or stimulus. For example, passive tumor 
targeting can be achieved using stealth liposomes, which circulate and release their drug cargo over days 
or weeks and accumulate in tumor tissue through leaky tumor vasculature via the EPR e#ect. 14, 100, 101 
Stealth liposomes have not been seen to penetrate deeply into tumor tissue, however, typically staying 
adjacent to blood vessels even two days a&er injection. 138 Moreover, slow drug release limits bioavailability 
even with long-circulating liposome accumulation into the tumor. 139 Despite these shortcomings, this 
passive targeting approach has been shown to produce 10-fold or greater drug delivery to a tumor 
over traditional chemotherapy. 140 Active tumor targeting can also be accomplished. For example, drug 
delivery can be achieved through incorporation of tumor-speci%c targeting ligands on the surface of the 
liposome, 141 as well as through liposomal components sensitive to stimuli such as pH, 142 electromagnetic 
radiation, 143 and enzymes. 144 In addition, tumors can be actively targeted by triggering intravascular 
release using temperature-sensitive liposomes (TSLs). 19, 20, 22, 145 
Chapter 2
19
TSLs can be characterized by a gel-to-liquid crystalline phase transition temperature (Tt), which depends 
on the composition of the lipid bilayer membrane. 12, 19 At temperatures well below their Tt, TSLs are 
relatively stable. At or above Tt, the lipid bilayer becomes permeable and TSLs release their contents. 
TSLs with a Tt above human body temperature can therefore be used for local drug delivery if the target 
region is heated locally. 19, 24 !ese types of liposomes have recently gained considerable attention and 
have been used or are planned to be used in several clinical trials. 24, 146-149 
Contemporary TSLs are designed to release their cargo (usually a chemotherapy agent) at mild 
hyperthermic temperatures above a certain threshold temperature, typically around 40–41 °C. 19, 21, 25, 
102 !ese kinds of liposomes, with release properties optimized for mild hyperthermia, are known as 
low-temperature sensitive liposomes (LTSLs), and they rapidly release their drug cargo upon being 
heated to their threshold temperature. 21 Fast-releasing LTSLs are well suited for intra-vascular triggered 
release, as they can release their contents within the transit time (a few seconds) of the tumor vascular 
network. 150-152 Preclinical studies combining LTSLs with local mild hyperthermia have demonstrated a 
significant tumor volume reduction in mouse tumor models compared with conventional free drug or 
non-thermally sensitive liposomes. 21, 22, 26, 27 Fig. 2.1 depicts targeted drug delivery resulting from the 
combination of mild hyperthermia and LTSLs.
Fig. 2.1. Representation of mild hyperthermia mediated LTSL drug delivery. A) At normal body tempera-
ture, LTSLs (blue circles) circulate through tumor vasculature. B) At temperatures above the phase transi-
tion temperature of the lipid bilayer, LTSLs rapidly release their drug cargo resulting in targeted drug 
delivery to the tumor. 
Although the e"cacy of LTSLs has been studied in both preclinical and clinical settings, precise 
spatiotemporal control of drug delivery from LTSLs has not yet been achieved. 22, 24, 137, 146, 147 Intra- and 
inter-patient spatial variability in tumor microenvironment, such as vascularity and perfusion, may 
impact both the heating pattern and delivery of drugs. 28, 29, 153 To accommodate this spatial variability, 
mild hyperthermia treatment may be adjusted for optimal drug delivery by using a control algorithm. 
!erefore, in addition to temperature monitoring, direct imaging of drug delivery (or an appropriate 
substitute, such as release of a contrast agent from LTSL) may improve real-time control of drug delivery 
or help guide future interventions. A suitable surrogate for quanti#cation of drug delivery may be 
provided by imaging contrast agent release from liposomes co-loaded with a drug and an MR contrast 
agent. 30
Contrast agents can be used to improve the visibility of internal body structures in an MR image, as well 
as to study the transport properties of tissue by examining the dynamic changes in contrast enhancement. 
!e #rst papers on liposomes loaded with MR contrast agents were published in the late 1980s. 154 !ese 
liposomes encapsulated high concentrations of hydrophilic contrast agents such as gadolinium-based 
Gd-DTPA. Recently, gadolinium-based contrast agents have been encapsulated in liposome interior 
compartment 31 as well as conjugated to their membrane, 32 or both. 33  
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Relaxivity is an ability of magnetic compounds (e.g., contrast agents) to modify the relaxation rates of 
the surrounding water proton spins. Most liposomes with gadolinium-based contrast agents in their 
interior compartment have a relaxivity lower than that of free contrast agent, because their liposomal 
membrane shields contrast agent in the interior compartment from bulk water outside the liposome. 155 
Such liposomes with contrast agents may be designed to report on drug delivery by contrast agent release. 
In fact, LTSLs that release contrast agent from their interior have been used to monitor release in vivo, 
demonstrating promising imaging correlations with both drug delivery 34 and therapeutic e!cacy. 30 "is 
ability may enable spatiotemporal control over drug delivery — a concept known as drug dose painting. 
30, 34 In this paradigm, the treating physician prescribes a desired drug dose and spatial distribution of 
drug to be delivered, and an image-guided mild hyperthermia applicator manipulates heat in the target 
region to achieve the desired drug dose. Fig. 2.2 illustrates the use of imageable-LTSLs (iLTSLs) and an 
MR-HIFU system for drug dose painting.
Fig. 2.2. A diagram showing the concept of drug dose painting using MR-HIFU and iLTSLs. The treating 
physician would select the area to deliver drug (green dashed circle), and the desired drug dose would 
be delivered preferentially to that region while the patient would be spared from the effects of systemic 
toxicity. A combination of MR imaging, HIFU heating, software-based automated feedback control, and 
iLTSLs would be used to plan, monitor, and control the treatment in real time.
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3  High-intensity focused ultrasound
3.1  High-intensity focused ultrasound physics
3.1.1 Therapeutic ultrasound and high-intensity focused ultrasound
Acoustic waves are propagating pressure variations in a medium. Ultrasound is de!ned as a pressure wave 
that propagates at a frequency above 20 kHz, the typical threshold for human hearing. "is longitudinal 
wave causes particles to oscillate back and forth and produce a series of compressions and rarefactions. 
Ultrasound waves deposit energy as they propagate through tissue, but the energy deposited by diagnostic 
ultrasound is insigni!cant, only slightly increasing tissue temperature (ΔT < 1.5 °C). 156 It is to be noted 
that ultrasound will not readily penetrate air !lled structures and thus cannot be used for imaging of, 
e.g., lung or bowel. 157
"erapeutic ultrasound is a branch in medicine where living tissues are exposed to ultrasound waves 
with the intention of achieving bene!cial results for health. "erapeutic applications of ultrasound pre-
date its use as a diagnostic imaging technique. In 1927, Wood and Loomis recognized that ultrasound 
could produce lasting changes in biological systems, and initiated both safety and preclinical studies on 
ultrasound therapy. 158
"erapeutic ultrasound operates according to the same physical principles as diagnostic ultrasound, 
although the total amount of deposited energy can be several orders of magnitude greater. "erapeutic 
ultrasound may be continuously applied for several seconds or even minutes. In contrast, diagnostic 
ultrasound is applied in short pulses of a few microseconds. "e resulting spatial-peak temporal-average 
intensity levels (Ispta), indicative of the magnitude of thermal bioe$ects, 159 are thus around 0.1–0.5 W/cm2 
for diagnostic ultrasound, even though the spatial-peak temporal-peak intensities (Isptp) can be similar 
as for continuously applied therapeutic ultrasound. 43, 49, 60, 160 Typically, the spatial peak intensity levels 
for modern ultrasound therapy devices are around 1000–4660 W/cm2 in situ, but can be signi!cantly 
higher. 44, 49, 161, 162 Consequently, the increase in e$ective focal point intensity with focused therapeutic 
ultrasound can easily be a factor of 1000 or more, as compared to non-focused plane waves in diagnostic 
use. "erapeutic ultrasound modalities include, e.g., histotripsy, 163 lithotripsy, 164 ultrasound-enhanced 
thrombolysis, 165 and HIFU. 
"e properties of HIFU allow it to be brought into a tight focus at a distance from its source, with high, 
localized pressures leading to temperature elevations achieved solely within the focal region. 49, 160 "e 
region or volume of elevated temperatures occurs without damage to surrounding tissues and can be 
targeted from outside the body, thus providing a noninvasive means to achieve hyperthermia (Fig. 3.1). 
A thorough overview of the fundamental principles of therapeutic ultrasound can be found in the MRI-
guided Focused Ultrasound Surgery book compiled by Jolesz and Hynynen. 166 
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Fig. 3.1. A) Schematic representation of high-intensity focused ultrasound producing localized, elevated 
temperatures deep within the body, without significantly heating surrounding tissues. B) Schematic repre-
sentation of a geometrically-focused spherical shell ultrasound transducer, showing near field, far field, 
beam path, aperture diameter, focal length, and the location of the focal point at the geometrical center 
of curvature. Depiction of the transducer, HIFU beam propagation, and the focal point are only illustra-
tive and not to scale.
3.1.2 HIFU transducer design 
Contemporary, clinical HIFU transducers are usually made of a piezoceramic or piezocomposite material, 
and come in the shape of a spherical shell. 50, 52, 55, 74, 167-170 A schematic representation of a geometrically 
focused spherical shell transducer is illustrated in Fig. 3.1. !is kind of transducer has a natural focus 
at or near its geometric center of curvature, and provides much higher focal intensity gain compared to 
a non-focused planar transducer with similar dimensions. !ese features are especially useful for deep 
penetration and heat localization. 74, 168
!e resulting focal point is ellipsoid in shape, the size of which depends on transducer geometry and 
dimensions as well as on the ultrasound wavelength, but is typically in the order of few millimeters as 
measured at -3 dB or -6 dB of acoustic pressure. 169, 171 !e wavelength λ, i.e., the distance between two 
compressions or rarefactions, is determined by the ultrasound frequency f according to 172
(3.1)
where c is the speed of sound in the attenuating medium. !e speed of sound in human so" tissues is 
usually very close to that of water, i.e., approximately 1540 m/s. 173-175 In practice, extracorporeal HIFU 
transducers employ frequencies in the range of 0.6–2.0 MHz, whereas interstitial and intracavitary 
transducers use higher frequencies in the range of 2–6 MHz. 50, 55, 60, 61, 162, 171, 176-178
For a typical HIFU transducer in clinical use, such as the one used in this dissertation work (Publications 
I–VI) with 256 elements, 12 cm radius of curvature (focal length), 13 cm aperture diameter, and operating 
at 1.2 MHz, the produced ellipsoid focal point is approximately 1.6 mm × 1.6 mm × 10 mm (-6 dB), as 
measured along the ellipsoid axes. 
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In ultrasound wave theory, a phased array is an array of transducers in which the relative phases of the 
respective driving signals can be adjusted so that the e"ective wave pattern of the array is reinforced 
in desired locations (constructive interference) and suppressed in undesired locations (destructive 
interference). 
A phased array HIFU transducer may consist of many small piezoelements, each of which can be 
individually controlled. 51, 74, 168, 179-182 By adjusting the phase and/or amplitude of the driving radiofrequency 
signal individually for each element, the focal point can be displaced from the nominal focus, or a pattern 
of multiple foci can be generated. 51, 77-79 In other words, the ultrasound beam can be steered or de#ected 
electronically. $is approach can be highly advantageous as it allows the heating of a larger volume as 
well as control of the shape of the heated volume without the need for mechanical displacement of the 
transducer, thus increasing both the #exibility and e%ciency of a HIFU therapy. Fig. 3.2 demonstrates 
electronic steering of a single focal point using a phased-array transducer.
To obtain constructive interference at the desired location by electronic steering, the required phase for 
a given drive signal can be determined using the equation
(3.2)
 
where l r rj j= −   denotes the distance from the center of the element rj  to the target focal point 
location r   (Fig. 3.2).
Fig. 3.2. Schematic illustration of a phased-array transducer, showing sinusoidal driving signals for each 
element. A) All elements are driven synchronously in phase, producing a focal point at the geometrical 
focus. B) By adjusting the relative phases of the drive signals, the focal point is displaced laterally (i.e., 
steered electronically). The l1 and ln denote the distances from the center of elements 1 (r1) and n (rn), 
respectively, to the target focal point location r.
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!e transducer design, i.e., its geometry and the number, location and size of the individual elements 
ultimately determine the volume within which the focal point can be steered, since the focal point has to 
be within the volume where all of the beams generated by the individual elements are overlapping. 166 If 
the focal point is steered outside of this volume, it results in loss of intensity at the intended focus, leading 
to inferior temperature elevation. Furthermore, it can lead to the generation of undesirable secondary 
focal points also known as side lobes, which usually occur in the opposite direction of de"ection when 
steering the focal point laterally, perpendicular to the beam axis. 166 Element diameter in clinical phased-
array HIFU transducers is typically around 2–10 mm, and thus they behave like directional radiation 
sources (element diameter > wavelength).  Accordingly, electronic steering range is usually limited to 
approximately ±10–15 mm perpendicularly to the beam axis, and ±20 mm along the beam axis. 51, 169, 179
!e design of the phased-array transducer greatly in"uences the extent and severity of the side lobes. 169, 
179 A symmetrically sectioned transducer surface with sizeable grating slits (i.e., areas that do not emit 
ultrasound) may result in moderate side lobes even without electronic steering, especially for transducers 
with a high degree of surface symmetry. Moreover, using these symmetrically designed transducers 
to perform electronic steering perpendicular to the beam axis may further escalate this problem. To 
remedy this, the symmetry of the element placement can be decreased by, e.g., utilizing a quasi-random 
design, thus reducing the extent of the side lobes and allowing for improved beam-steering. 74, 168, 183, 184 
For manufacturing reasons, however, most transducers have some areas (between the elements) that do 
not emit ultrasound, resulting in minor side lobes that may or may not be insigni#cant, depending on 
the application.
3.2  HIFU platform
Due to a high characteristic acoustic impedance mismatch between water and air, ultrasound waves 
cannot readily propagate between the two media and therefore require a clear acoustic path between 
the transducer and target tissue. For modern clinical MR-HIFU platforms, this is typically achieved by 
immersing the transducer in a degassed water tank sealed with a very thin (50–100 µm) and acoustically 
transparent plastic membrane. 50, 55, 71, 170 !e water tank is usually integrated into an MR-compatible patient 
table that also houses the matching electronics as well as an electromechanical transducer positioning 
system to enable accurate targeting. To assure and further improve acoustic coupling between the plastic 
membrane and the patient’s skin, a gel pad together with ultrasound gel can be used. 50, 52 !e MR-HIFU 
patient table is commonly incorporated into a freely movable unit that can be docked to the MR scanner 
for MR-HIFU therapy, and stowed away between procedures. 
A clinical MR-HIFU therapy system (Sonalleve V1, Philips Healthcare, Vantaa, Finland) was utilized 
in this dissertation work for publications I–VI. !is system consists of a patient table that houses the 
transducer as well as the positioning system. In addition, the system includes radiofrequency generators 
and ampli#ers, control and matching electronics, MR receive coil, and a PC workstation with clinical 
so$ware. 
A clinical HIFU table may not be well suited for small animal studies, however, and might need an adapter 
for optimal coupling and animal positioning. An example of such adapter that contains an additional 
unsealed water bath located above the patient table, as well as a dedicated MR receive coil better suited 
for animal studies, is depicted in publication II.
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3.3  Interaction of high-intensity focused ultrasound with tissue 
3.3.1 Physical effects and mechanism of therapeutic action
Acoustic energy in tissue expresses itself as vibrational forces that are applied on every tissue component, 
such as intra- and extracellular !uids and cell membranes. An ultrasound wave propagating through 
the body may experience multiple and complex physical interactions between the wave and tissue that 
are capable of causing loss or redirection of acoustic energy. "ese interactions include reflection and 
refraction due to acoustic impedance mismatch between tissues, di#raction along inhomogeneous tissue, 
scattering, and absorption. Among these physical phenomena, scattering and absorption are thought to 
contribute the most to acoustic energy attenuation. As ultrasound energy is absorbed, it is converted to 
heat. When ultrasound is scattered due to tissue inhomogeneities, it is eventually absorbed elsewhere. 
166, 185, 186 A detailed explanation on the interaction of ultrasound with biological tissues as well as of the 
principles of therapeutic ultrasound can be found in the Physical Principles of Medical Ultrasonics book 
compiled by Hill, Bamber, and ter Haar. 43
HIFU bioe#ects can be grouped into e#ects that are predominantly thermal or predominantly non-
thermal (known as mechanical) in origin, and can be manipulated by adjusting ultrasound output power, 
frequency, duty cycle, sonication duration, and focal point characteristics. Non-thermal mechanisms can 
further be separated into cavitational and non-cavitational (not bubble-related) mechanisms. "ermal 
e#ects are due to ultrasound absorption and conversion to heat through vibrational excitation of tissue, 
leading to frictional heating and rapid, highly localized temperature elevation. Mechanical bioe#ects 
include acoustic radiation forces and acoustic cavitation, which is mediated by bubble activity. Bubbles 
produced by cavitation are formed due to high negative peak pressures during the rarefaction phase of 
the ultrasound wave, and have been observed to prevent delivery of desired energy levels to the target 
region. In addition, collapsing or oscillating bubbles may lead to locally induced mechanical damage and 
enhanced heat absorption. 42, 186-188
In the absence of blood !ow, the rate of heating is determined by the attenuation coe$cient, which is related 
to the density of the tissue and the ultrasound frequency. 166, 189 In the therapeutic ultrasound frequency 
range of interest, the relationship between ultrasound frequency and attenuation is approximately linear, 
i.e., higher frequencies cause an increase in attenuation. 43, 166 Ultrasound attenuation varies signi%cantly 
between so& tissues, however, with a typical range of 0.3–2.0 dB/(cm·MHz), depending on tissue type. 
Attenuation for biological !uids can be much lower at around 0.1 dB/(cm·MHz), and much higher for 
bone at around 20 dB/(cm·MHz). 43, 173, 175 
"e e#ects of HIFU on tissue are dependent on the acoustic pressure in the focal region, with di#erent 
mechanisms of energy propagation dominating at di#erent acoustic pressures. At low pressures, the 
acoustic %eld is predominantly linear and acoustic intensity is proportional to the pressure squared. At 
higher pressure levels, the peak negative (rarefaction) pressure correlates well with the onset of cavitation 
e#ects, 44, 190, 191 and nonlinear wave propagation leads to generation of higher harmonics. 192 Assuming 
linear acoustics in which the medium density and acoustic pressure have linear relationship, the pressure 
amplitude p(x) of a propagating ultrasound wave is attenuated according to equation 172
, (3.3)
where x is the tissue depth, p0 is pressure at x = 0, and α is the attenuation coe$cient, which is the sum of 
the absorption and scattering coe$cients αa and αs. 
At the typical pressure levels produced by HIFU, however, the ultrasound propagation may be non-
linear. "e higher harmonic components of the fundamental frequency generated by the non-linearity 
are absorbed more rapidly, and thus may signi%cantly increase local energy absorption especially in the 
focal region, thereby increasing the heating rate. 193-195  
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3.3.2 Temperature rise induced by HIFU 
!e tissue temperature distribution T r t( , )  caused by energy absorption is o"en described using the 
Pennes’ Bioheat Transfer Equation (BHTE) that takes into account heat di#usion as well as heat loss by 
perfusion. HIFU induced temperature rise as estimated by BHTE can be given by 196
,
(3.4)
where ct is the speci$c heat of the tissue, ρt is the density of the tissue, kt is the thermal conductivity of 
tissue, cbl is the speci$c heat of blood, ρbl is the density of blood, wbl is the blood perfusion rate, Tbl is the 
arterial blood temperature, and Q r t,( ) is the HIFU heat source term.
!e energy absorption in tissue can be modeled as a function of the acoustic pressure amplitude p by 172
, (3.5)
where α is the attenuation coe%cient, and c is the speed of sound in the tissue. 
Since peak acoustic intensity I as a function of acoustic pressure for a plane progressive wave is 172
, (3.6)
the BHTE can be written using the product of acoustic intensity and attenuation as the heat source term 
.
(3.7)
Speed of sound c in so" tissues varies slightly based on temperature, but is typically close to that in water, 
approximately 1540 m/s 173, 175. !ermal conductivity k for most so" tissues is around 0.6 W/(m·°C), with 
the exception of fat. Fat is a relatively good insulator and consequently has a thermal conductivity around 
0.2 W/(m·°C). 175, 197 In addition to constants α, c, and kt being tissue dependent, however, physiological 
processes such as thermal coagulation change the properties of the heated tissue. 198 Furthermore, 
perfusion reduces the heating e%ciency, and this e#ect can be signi$cant in highly perfused organs such 
as kidney and liver, as well as in so" tissue tumors. 199-202 !us, ultrasonic properties of tissue vary both 
in place and in time, and the exact temperature distributions in the target tissue cannot be theoretically 
calculated. For this reason, it is important to monitor the HIFU induced temperature elevations in real 
time not only in the target region, but in surrounding tissues as well.
3.3.3 Thermal dose
As with any thermal therapy, accurate temperature monitoring and methodical dosimetry are required 
to accomplish a bene$cial and veri$able treatment outcome. Parameters such as minimum or average 
temperature, as well as the tenth percentile of the temperature distribution (T90) based on multipoint 
thermometry have o"en been used. To manage temperature variations and diverse heating durations 
between patients, temperature data have been converted to quanti$able thermal dose, de$ned, e.g., as 
cumulative equivalent minutes at 43 °C (CEM43) at the minimum, average, or T90 temperature point 
to enable comparative analysis. 123, 203 Many mild hyperthermia clinical trials have shown a positive 
correlation between thermal dose and treatment outcome. 105, 123, 124 
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!e concept of CEM43 thermal dose as a function of temperature and time was developed to quantitatively 
describe the e"ect of temperature elevation on tissue, and is de#ned in terms of equivalent minutes at the 
reference temperature of 43 °C.
!e thermal dose a$er heating for time t is de#ned as 203 
,
(3.8)
where TD r t43 ,( )  is the thermal dose in equivalent minutes at 43 °C, T r ,τ( )  is the tissue temperature, 
and R is a constant that equals 0.5 above 43 °C and 0.25 below 43 °C. 203 !e threshold for coagulative 
necrosis is thought to be between 50–250 CEM43, depending on the tissue type, 51, 204-207 while thermal 
dose values of 10–50 CEM43 have been shown to provide a therapeutic e"ect in mild hyperthermia 
treatments. 208, 209 !ermal dose threshold of 240 CEM43 is generally considered as a good descriptor 
for irreversible thermal damage in most tissue types, 51, 206, 210-212 and is thus used in Publication VI as an 
indicator for complete coagulative necrosis. 
3.4  Sonication strategies for mild hyperthermia
Typical focal point size for a HIFU transducer in clinical use is on the order of a few millimeters. On the 
other hand, the size of the target region in mild hyperthermia therapy may be signi#cantly larger than 
the size of the focal spot: up to several centimeters in diameter. Furthermore, it would be preferable to 
simultaneously heat the whole target volume of cancerous tissue and keep it at an elevated temperature 
for up to an hour. 3, 4 An o$en used strategy for HIFU thermal ablations is to sequentially sonicate a 
number of focal points one at a time until the desired volume is ablated. 55, 170, 211, 213-215 !is point-by-
point sonication method is inherently ine%cient, however, since a large part of the thermal energy is 
lost via heat di"usion out of the small sonication volume without being utilized for heating the target 
volume. Furthermore, this approach requires long treatment times since a large number of single point 
sonications are typically needed to cover the whole target volume, each separated by a cooling period 
to allow for transducer repositioning. Since mild hyperthermia therapy typically requires that the entire 
target lesion is heated for a long duration, the sequential point-by-point heating approach is not suitable 
for HIFU mediated mild hyperthermia. Clearly, other strategies for heating larger volumes to mild 
hyperthermic temperatures are required. 
One such strategy is to move the transducer during a sonication to simultaneously heat a larger region 
by mechanically scanning the focal point within the target volume. 81, 137, 216-218 !is sonication method 
tends to be relatively slow, however, and therefore is not well suited for maintaining large volumes at the 
target temperature range. 81, 218 In addition, this method may also be problematic to implement together 
with MR-imaging guidance, since a moving object with a substantially di"erent magnetic susceptibility 
than its surroundings (i.e., an air-#lled transducer in a liquid-#lled tank) may cause perturbations in the 
magnetic #eld and ultimately lead to artifacts in the temperature images. 23, 219
An alternative to mechanical transducer displacement is to utilize the electronic beam steering 
capabilities of a multielement phased array HIFU transducer. In this strategy, the focal point is rapidly 
steered along a single trajectory or multiple trajectories that can either be predetermined, or calculated in 
real time based on the resulting temperature distribution. Multiple locations can also be simultaneously 
sonicated by precisely adjusting the relative phases of the ultrasound driving signals and thus splitting 
the focus into multiple simultaneous foci. 78, 79, 168, 220 Furthermore, these multiple foci may be utilized 
for temporal switching between predetermined focal patterns while continuously sonicating. 77, 180, 221, 222 
While multifoci sonication approaches have been described to cause side lobes in ablative hyperthermia, 
74, 168, 182 these side lobes should not cause major problems in mild hyperthermia therapy due to the low 
acoustic pressures required by such treatments.
High-intensity focused ultrasound
TD r t R d
t
T r
43
0
43, ,( ) = ∫ − ( )τ τ
28
Sonication strategies of electronically sweeping a single focus point and simultaneously sonicating 
multiple concurrent foci may allow accurate and uniform mild hyperthermia in volumes much larger 
than a single focal point, while keeping the transducer stationary. !ese approaches for mild hyperthermia 
therapy were implemented on a clinical HIFU system, and tested and characterized in publications I 
and II. Furthermore, the single focus sweep strategy was employed in publications III, IV, and V for 
characterization of MR-HIFU mild hyperthermia mediated drug delivery. 
!e volumetric sonication approaches utilized in publications I–VI use the multiple outward-moving 
concentric circle trajectory concept originally proposed by Köhler et al. 51 In this concept, the circular 
trajectories are positioned in a plane perpendicular to the ultrasound beam axis and centered on the axis 
of propagation. Each circle contains multiple predetermined focal points that are evenly positioned on 
the circumference of the circle of a prescribed size. Examples of these circular trajectories are depicted 
in Fig. 3.3. In theory, however, these "exible volumetric sonication methods can utilize practically any 
trajectory shape, and may be designed and optimized according to patient- or application-speci#c 
requirements. While either mechanical transducer movement or electronic steering alone increase the 
volume that can be maintained at mild hyperthermia, the combination of these two methods may allow 
much larger volumes to be accurately heated.
Fig. 3.3. Examples of circular sonication trajectories. A) 2 mm single sonication point. B) 4 mm circular 
sonication trajectory with 8 focal points. C) 16 mm circular sonication trajectory, which consists of four 
concentric subtrajectories: 4 mm circle (8 points), 8 mm circle (16 points), 12 mm circle (24 points), and 
16 mm circle (32 points). In all trajectories, the focal points can be sonicated sequentially by electroni-
cally sweeping a single focus, or sonicated simultaneously by using multiple, concurrent foci.
3.5  Feedback controlled mild hyperthermia
Local, image-guided mild hyperthermia, especially in combination with temperature sensitive 
chemotherapeutics, is a clinically attractive and potentially feasible strategy for augmenting cancer 
therapies. For this strategy to realize its full potential, however, a hyperthermia applicator must be able to 
maintain accurate and homogenous heating in the cancerous target region while avoiding temperature 
rise in adjacent normal tissues.
With HIFU, the energy deposition and therefore the temperature increase and distribution depend on 
several tissue-speci#c parameters, such as ultrasound attenuation, heat di$usion, and tissue perfusion 
that are typically unknown. !erefore, it may be di%cult to estimate the appropriate power level to achieve 
and maintain the desired narrow target temperature range. To overcome this problem, several feedback 
algorithms using real-time thermometry data have been proposed, with the objective of generating a 
spatiotemporally controlled temperature pro#le at the target region. 
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Feedback algorithms may allow for a fully controlled therapeutic procedure, ensuring that the correct 
amount of thermal energy is deposited at the targeted location while the adjacent, healthy tissues remain 
unheated. MR thermometry can be utilized to perform either operator adjustable or fully automated 
feedback control of HIFU therapy to improve the temperature accuracy and uniformity, as well as the 
overall treatment e!cacy and safety. 88,96-100
Current approaches for MR-HIFU feedback algorithms concentrate on the use of binary, proportional-
integral (PI), or proportional-integral-derivative (PID) feedback control. 23, 72, 223-225 For example, feedback 
control methods in combination with spiral trajectories have been proposed for creating an accurate and 
uniform temperature elevation in the treatment volume. "e acquired temperature data can be used to 
modify either the velocity of the focal point along the spiral trajectory, 81 or reoptimize the trajectory 
points a#er each spiral has been sonicated. 226 More advanced feedback methods have also been proposed, 
such as feedback control of the thermal dose and a 3D spatiotemporal temperature control scheme in a 
user-de$ned region of interest. 72, 227 
While these methods have been able to produce the desired thermal performance both in vitro and in 
vivo, most of these approaches are targeted for relatively short duration thermal ablations, 73, 80 or rely 
in part on a priori estimates of the energy absorption, heat di%usion, and local perfusion to prescribe 
an applied power. 81, 228 "ese tissue properties are known to be spatially heterogeneous and di!cult or 
impossible to measure in vivo, potentially hindering the introduction of PI or PID feedback methods into 
clinical MR-HIFU mild hyperthermia work&ow. 
In publication I, a non-parametric binary mild hyperthermia feedback algorithm was designed and 
implemented on a clinical MR-HIFU system. "is algorithm uses a temperature-based feedback approach 
that requires no prior knowledge of tissue-speci$c parameters, but instead monitors and responds to the 
actual measured temperature distribution in the target region. "e control scheme can utilize multiple 
predetermined heating trajectories to produce and maintain accurate and homogeneous heating. 
Trajectory geometry and size, applied power, target temperature range, and therapy duration are set by 
the user. "e trajectory shape and size can be arbitrary, and the feedback criteria can include minimum 
temperature, mean temperature, T90, or thermal dose. "e algorithm functions by comparing calculated 
temperatures to predetermined temperature limits, and switches the sonication trajectories accordingly. 
"e simple design of this algorithm also provides robust control in the presence of disturbances, such as 
those related to sudden motion. Since the control scheme is based on sonication time while sonication 
power is limited in mild hyperthermia applications, there is no need for a smooth ramping to target 
temperature as is necessary for some parametric controllers, 23, 72, 82, 226 and thus rapid heat-up is possible. 
Comparative simplicity of the binary algorithm makes it an attractive candidate for clinical translation. 
Furthermore, regulatory implications may be more favorable for a simple and robust temperature 
feedback algorithm such as the one presented in publication I. 
Despite the simplicity of concentric subtrajectories and binary control, the binary feedback algorithm 
presented in publication I does have some disadvantages. Since electronic steering can only be used 
to cover a relatively small volume, the binary approach cannot be used to heat much larger lesions 
commonly encountered in the clinic. In addition, the pre-de$ned subtrajectories used in the current 
binary implementation may not be adequate for heating spatially heterogeneous tissue, where dynamic 
changes in subtrajectory may be required for homogeneous heating. Even with these disadvantages, the 
binary feedback algorithm allowed for robust volumetric heating control, permitting examination of 
MR-HIFU mediated drug delivery in publications III and V.
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4 Magnetic resonance guidance of 
high-intensity focused ultrasound 
mediated mild hyperthermia
4.1  Magnetic resonance imaging
Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique used to produce detailed 
images of the body. !e main advantage of MRI is that it does not rely on ionizing radiation to acquire 
images. Instead, MRI employs magnetic "elds, magnetic "eld gradients, and radio frequency (RF) pulses. 
229 MRI o#ers a variety of mechanisms to provide so$-tissue contrast, and it can highlight structural 
di#erences on both macroscopic and microscopic level in biological tissues. In addition, MRI can achieve 
excellent anatomical resolution and can be used to obtain images in any scan plane. 229 MRI is therefore 
well suited to depict and di#erentiate healthy and pathological tissues. As an added bene"t, several 
MRI parameters are temperature sensitive, enabling noninvasive monitoring of temperature elevations 
during therapy by employing suitable MRI sequences. 48, 53 Consequently, MRI plays an important role 
in planning and monitoring surgical interventions and minimally invasive alternatives to surgery, such 
as HIFU. 46, 71, 166  
MRI exploits the physical properties of an atomic nucleus to induce measurable signals from the atoms 
of an object that is being imaged. !e roots of MRI date back to 1938, when Isidor Rabi developed a 
new method for measuring the nuclear magnetic moment. 230 Later in 1946, Felix Bloch and Edward 
Purcell showed that the Nuclear Magnetic Resonance (NMR) phenomenon also exists in solid and liquid 
materials. 231, 232 !e basis of the NMR e#ect is simply that nuclei in a magnetic "eld absorb and remit 
electromagnetic radiation at a speci"c resonance frequency (Larmor frequency) that depends on the 
strength of the magnetic "eld and the magnetic properties of the isotope of the atoms. 
In the following sub-chapters, MRI-based therapy planning and monitoring, as well as MRI-based 
veri"cation of therapy outcome are brie%y discussed. A detailed explanation of NMR from the quantum 
point of view as well as descriptions of macroscopic magnetization, spin relaxation, and spatial encoding 
can be found in the excellent Magnetic Resonance Imaging book by Stark and Bradley. 229
4.2  MRI-based therapy planning for mild hyperthermia therapy
MRI o#ers many advantages over other imaging techniques, such as ultrasound and computed 
tomography. Since MRI is devoid of ionizing radiation, it is of particular use in malignant tumor cases 
where repeated imaging may be necessary to monitor the progress of the disorder. Additional advantages 
include the ability to directly obtain images in multiple planes. Using contemporary clinical MR scanners, 
there is enough variation between intrinsic, tissue-speci"c MR parameters, such as T1, T2, or proton 
density, to permit image acquisition with excellent contrast between so$ tissues, and between normal 
and abnormal morphology/pathology. 229 Furthermore, the e#ect of these tissue-speci"c parameters 
on the MR image contrast can be adjusted using a set of operator-selectable parameters, such as pulse 
repetition time (TR), echo time (TE), and %ip angle (FA). 229 In addition, the use of an intravascular 
contrast agent (e.g., gadolinium chelates) may reveal physiologic changes in tissue that are associated 
with the underlying pathologies. !us, in clinical practice, MRI is typically used for delineation of so$ 
tissues, to determine extent and spread of disease, for staging of di#erent tumors, to obtain functional 
and metabolic information, and for monitoring therapy response. 229
!e ability of MRI to display so$-tissue contrast and provide highly detailed images of the human 
body makes this noninvasive imaging modality also ideal for planning image-guided therapies, such 
as HIFU mediated mild hyperthermia. Treatment planning can be optimized by using so$ware tools 
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and computer-assisted tissue delineation. For example, MR images can be shown within a graphical 
user interface and used in HIFU mild hyperthermia therapy planning to precisely de!ne the treatment 
volume and HIFU beam path, as well as examine possible safety concerns, such as proximity of air 
!lled cavities (e.g., lungs, bowel). "is allows visualization and real-time adjustments of the therapy 
plan. "erapy planning may further be improved by superpositioning graphical overlays of, e.g., the 
transducer position, HIFU beam path, and target volume on the planning images. An example of HIFU 
mild hyperthermia therapy planning in an animal model is depicted in Fig. 4.1.
Fig. 4.1. Planning for MRI-guided mild hyperthermia: A) Coronal MR image, B) Sagittal MR image. Tu-
mor (hyper-intense) was identified (white dashed line) on the proton density-weighted planning images, 
and target regions within the tumor were chosen (green circles). Image reproduced with slight modifica-
tions from Publication II with permission from AAPM.
4.3  Treatment monitoring by magnetic resonance thermometry
In mild hyperthermia therapy, the dependence of treatment success on achieved thermal dose highlights 
the requirement for precise temperature elevations and accurate thermal dosimetry. Invasive thermometry 
methods, such as insertion of thermocouples, su#er from poor sampling of just a few points in target 
tissue, with little to no sampling of surrounding tissues. 103, 187, 193, 233 In addition, this method is plagued 
by di$cult placement and localization of the thermocouples, and may introduce imaging artifacts. 103 On 
the other hand, infrared cameras can detect temperature changes at submillimeter resolution, but in vivo 
measurements using this technique are limited to tissue surface. 234 "e challenge of performing accurate 
thermal dosimetry has been one of the biggest hurdles in clinical mild hyperthermia therapy to date. 3 
At present, thermotherapies are monitored and guided by either ultrasound 233, 235, 236 or MRI. 48, 53, 57 Due to 
its availability, low cost, and easy application methods, ultrasound has been seen as the natural medium to 
direct HIFU therapy. Using the same medium as the thermotherapy itself would also seem sensible. "e 
clear disadvantage of ultrasound is the relatively poor quality of images that can be di$cult to interpret. 
In addition, ultrasound is incapable of concurrent treatment monitoring in multiple planes. Finally, 
despite promising experimental results, development of suitable ultrasound thermometry methods for 
real-time therapy monitoring in the clinic has been slow. 237 MRI currently o#ers the best solution for 
noninvasive assessment of temperature changes in tissue. 237 Several MR parameters are temperature 
sensitive, including di#usion coe$cient, T1 relaxation constant, bulk magnetization, and water proton 
resonance frequency. 48 "e water proton resonance frequency shi% (PRFS) method 47 has been shown to 
deliver the best temperature sensitivity, however, providing a temperature standard deviation of less than 
1 °C at a temporal resolution below one second and a spatial resolution of roughly 2 mm. 53 
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In addition, the PRFS method is nearly independent of tissue type and has excellent linearity of temperature 
dependency in non-adipose tissues. 48, 53 !us, the PRFS method is currently the most commonly used 
for MR thermometry. 48 !e PRFS of adipose tissue is not linearly dependent of temperature, however, 
and therefore fat suppression techniques are required in most biological tissues. 238, 239 PRFS-based MR 
thermometry was used in Publications I–VI, and its principles as well as its limitations are described 
below. Details on other MR thermometry techniques can be found in the review papers by Quesson et al. 
53 and Denis de Senneville et al. 48
4.3.1 Proton resonance frequency shift thermometry
Hindman "rst discovered PRFS’s dependency on temperature in 1966, 240 when observing intramolecular 
forces and hydrogen bond formation between water molecules. Shielding by the surrounding molecules 
and electrons results in local variations in the B0 main magnetic "eld experienced by individual protons. 
In water, the shielding is due to electrons of the hydrogen atoms. !e electron cloud shields a hydrogen 
nucleus from the main magnetic "eld more e#ciently when the nucleus is part of a free water molecule, 
as compared to a water molecule that is hydrogen bonded to another water molecule. !is is because 
the hydrogen bonds distort the electronic con"guration of the water molecules, thereby reducing the 
electronic shielding. !e fraction of hydrogen bonded water molecules depends on the temperature. As 
temperature increases, the instability of hydrogen bonds also increases, and the molecules spend less 
time in a hydrogen-bonded state. 240, 241 !is increases molecular shielding σ(T) seen by the hydrogen 
nuclei and makes the local magnetic "eld Bloc experienced by nuclei temperature dependent according to equation 242
, (4.1)
where δ(T) is the resulting small di$erence in the proton resonance frequency, and is referred to as the 
chemical shi%. Consequently, the proton resonance frequency also depends on temperature, and can be 
expressed as 242
, (4.2)
where f0 is the Larmor frequency.
!e chemical shi%, which is reduced by the increase in molecular shielding, has almost linear temperature 
dependence that can be given as 242
, (4.3)
where δ0 is the part of chemical shi% that is independent of temperature, and αT is the temperature 
dependency coe#cient in ppm/°C. For water protons, αT is -0.0108 ± 0.0001 ppm/°C. For so% tissue, 
αT  is typically between -0.009 and -0.01 ppm/°C, linearly dependent on the temperature within the 
temperature range of interest for hyperthermia, and nearly independent of tissue composition. 53, 240, 242, 243 
!e decrease in the local magnetic "eld Bloc due to change in the temperature dependent chemical shi% will also lower the proton resonance frequency that is linearly dependent on the local magnetic "eld. 
231, 232 !e temperature dependent shi% in resonance frequency, and thus also the chemical shi%, can be 
calculated from the phase maps generated, e.g., by gradient echo sequences, 47 as the signal phase Φ is 
directly proportional to the chemical shi% according to 40, 41
(4.4)
where γ is the gyromagnetic ratio and TE is the echo time.
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In order to measure only the temperature dependent change in the chemical shi!, the temperature 
independent contribution δ0 caused by B0 "eld inhomogeneities must be removed. #is is typically achieved by subtracting a reference phase map at a known baseline temperature from the phase map 
acquired at temperature T. #us, the change in temperature can be calculated according to 48, 242
(4.5)
where Φ(Tref) is the corresponding reference phase at a known baseline temperature Tref .
Accordingly, the PRFS technique is only capable of calculating relative temperature change, and not 
absolute temperatures. #erefore, the core body temperature is typically measured prior to therapy, and 
used as the baseline reference temperature Tref, to which temperature change maps are added to obtain 
absolute temperature maps. 
Using the PRFS method for thermometry at 1.5T "eld strength, with a TE of 20 ms, and with a signal-
to-noise ratio (SNR) of 40, the theoretical temperature standard deviation can be as low as 0.3 ºC. 81 
#erefore, the PRFS method can achieve excellent temperature sensitivity.
An example of PRFS-based temperature monitoring during MR-HIFU mediated mild hyperthermia in 
an animal model is depicted in Fig. 4.2.
Fig. 4.2. PRFS-based temperature mapping for MR-HIFU mild hyperthermia: A) Coronal MR image, B) 
Sagittal MR image. Temperature maps (color scale) are overlaid on dynamic magnitude images (gray-
scale), showing typical temperature distribution during HIFU heating. Target temperature range was 
40.5 –41 ºC. Heating location corresponds to target region 4 in figure 4.1. Image reproduced from 
Publication II with permission from AAPM.
4.3.2 Complications of PRFS thermometry due to fatty tissues, motion, and magnetic 
¿HOGGULIW
#e temperature dependence of PRFS in aqueous so! tissues has been shown to be nearly the same 
as in water. 48 In pure lipids, however, there are no hydrogen bonding interactions between molecules 
and thus the shielding constant does not vary signi"cantly with temperature. 240 #e PRFS of lipid 
hydrogen is therefore nearly independent of temperature, and the presence of even small amount of 
lipids in tissue may lead to signi"cant errors in PRFS-based temperature maps. 238 To overcome this 
problem, fat suppression or spectrally selective excitation techniques can be applied to preferentially 
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image water protons, 244-246 thus allowing for accurate PRFS-based thermometry in tissues where both fat 
and water protons are present. 239 Regrettably, the fat signal cannot be completely suppressed due to the 
multiple resonance peaks present in fat (particularly the ole!nic peak near water peak), and due to B0 
!eld inhomogeneities within the volume of interest. 
Motion-related MR image artifacts occur when the imaged object moves during image acquisition. 
While registration and motion correction algorithms can be used to align the image with a reference 
image in order to correct for most bulk motion and avoid artifacts in the temperature images, there 
are motion-induced artifacts that cannot be corrected with registration. For example, B0 !eld changes 
occur due to tissue motion, since the local magnetic !eld varies as the target tissue moves within the 
largely inhomogeneous magnetic !eld inside the body. Some of the most common motion-induced !eld 
changes occur due to breathing and cardiac motion, even at locations distant from the source of motion. 
"ese !eld changes may then result in phase changes in the images, which in turn cause temperature 
errors in PRFS-based MR thermometry. For example, breathing motion has been shown to induce !eld 
changes in the brain, 247, 248 abdomen, 249 and breast. 250, 251 "erefore, correct phase reference needs to be 
applied to enable accurate PRFS thermometry of or within close proximity of moving organs or objects. 
Many techniques have been developed to correct for these motion-induced phase changes and to provide 
a correct phase reference. Techniques include averaging or !tting of the MR data, but these methods 
typically require complex mathematical operations performed retrospectively, and may not be feasible 
for real-time use. 252, 253 In addition, navigator echoes for respiratory gating 254-256 as well as calculating 
di#erences in tissue position 257 have been used to estimate phase changes. Reference images taken at 
multiple stages of the breathing cycle (i.e., a multibaseline approach) can also be used in combination 
with respiratory gating to improve phase correction. 251, 258
MR-HIFU mediated mild hyperthermia also poses a challenge not typically present in thermal ablation 
therapies in regards to MR thermometry. "e duration of mild hyperthermia is usually much longer than 
that of an ablation, with typical treatment times in the order of tens of minutes and possibly as long as 
several hours. "e B0 magnetic !eld of modern MR scanners will dri$ over time when the gradients are 
intensely utilized. 259 "is dri$ then causes non-temperature-related phase changes that are inseparable 
from temperature-related phase changes. Consequently, mild hyperthermia treatment durations allow 
for signi!cant errors in temperature mapping. "e exact amount of error on temperature depends on the 
type of magnet and gradient coils, performed calibrations, and the duration of therapy, but in modern 
well-calibrated systems can be in the order of 10 °C per hour. Taking into account that the intended 
temperature elevation for a typical hyperthermia treatment lies within 3–8 °C, !eld dri$ could pose 
a signi!cant problem for temperature measurements if le$ uncorrected. Several methods have been 
developed to correct for the error arising from !eld dri$. One common approach is to provide reference 
regions in the image that change phase with magnetic !eld dri$ but remain unheated, i.e., do not change 
phase with temperature. If the !eld dri$ varies spatially, an improved compensation can be achieved 
by !tting a polynomial curve to the spatial distribution of phase in the unheated reference region 
and subtracting this !tted phase from the acquired phase images. Other approaches include placing 
references (in thermal equilibrium) around the target and calculating the phase changes due to B0 dri$ 
from these references. 238, 259 In addition, it has been shown that body fat or external water can be used as 
the reference material. 260
Alternative PRFS-based methods for MR-HIFU include referenceless thermometry that is used to 
monitor phase change in surrounding unheated tissue and to extrapolate the phase correction into the 
heated tissue. "is technique utilizes a polynomial !t of the phase 261, 262 or complex data 263 from the 
unheated area to estimate the background phase in the heated area. "e background phase, i.e., the 
estimated phase in the heated area had it not been heated, is used as the phase reference. "us, the e#ect 
of !eld dri$ is already included in the unheated area from which the reference phase is estimated, and a 
!eld dri$ correction is therefore not required. Disadvantages of this technique include the requirement 
for a relatively high SNR. In addition, the heating needs to be con!ned to a small well-de!ned area for 
the polynomial !t of the phase reference to be reliable, and thus this method may not be well suited for 
monitoring large volume MR-HIFU mild hyperthermia.
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4.4  MRI verification of treatment outcome 
While thermometry based thermal dose estimates have been used extensively as descriptors for assessing 
mild hyperthermia treatment outcomes, 105, 123, 124 other in vivo imaging methods are needed to quantify 
delivered drug, or to evaluate tissue damage resulting from ablative hyperthermia. !e tissue e"ects of 
MR-HIFU mediated mild and ablative hyperthermia may result in changes in such MR tissue parameters 
as T1 and T2 relaxation constants, as well as in the magnetization transfer constant. 264-266 !ermally 
induced changes in tissue perfusion, di"usion, and sti"ness may also be assessed using MRI. 265-270
T2-weighted imaging and contrast-enhanced imaging (CEI) are the two most commonly used MR-
imaging methods to evaluate hyperthermia-induced tissue damage. !e T2 relaxation constant may 
change as a result of hyperthermia induced tissue damage. 264, 266 Consequently, T2-weighted imaging 
can be used to locate the area of HIFU-induced thermal damage, 46, 57, 71, 264, 266 and previous studies have 
reported a good correlation between histological and T2-weighted assessments of the thermal lesion size 
and shape post-therapy. 207, 271, 272 Similar comparisons between thermal dose and T2-weighted assessment 
of the thermal lesion have also been described. 206, 207 T2-weighted MRI is of limited use in assessing mild 
hyperthermia therapy, however.
On the other hand, CEI can be used to monitor MR-HIFU mediated drug delivery in combination with, 
e.g., imageable liposomes, as shown in publication IV. In addition, CEI can be utilized for evaluating the 
extent of coagulative necrosis post-treatment as exempli#ed in publication VI. !e use of CEI to monitor 
iLTSL drug delivery as well as to assess therapy outcome of ablative HIFU is described below. Other 
imaging methods for veri#cation of treatment outcome are also brie$y discussed.
4.4.1 Contrast-enhanced MRI
MRI contrast agents alter the relaxation times of nuclei within tissues where they are present a%er 
administration. Most clinically used MRI contrast agents are administered intravenously, and function 
by shortening the T1 relaxation time of nearby nuclei. In mild hyperthermia drug delivery utilizing iLTSL, 
CEI can be used to evaluate T1-weighted signal intensity prior to and a%er imageable liposome injection, 
as well as to image contrast agent release in real-time or during and/or a%er each HIFU exposure. Direct 
imaging of delivered drug or an appropriate surrogate in the form of an MR contrast agent may improve 
real-time control of drug delivery or help guide and localize future interventions. 30 An example of the 
use of this technique is depicted in Fig. 4.3. 
On the other hand, tissue vasculature may be necrotic within thermally coagulated tissue. 270-273 
Consequently, the thermal lesions induced by ablative HIFU appear as hypointense (non-enhancing) 
regions in T1-weighted CEI due to reduced contrast agent delivery to these non-perfused regions. 207, 
256, 267, 270, 272 Good correlation has been shown between histological and CEI assessments of HIFU-
induced regions of thermal coagulation. 206, 207, 256, 272 Because of this correlation to the gold standard 
of histology, CEI has been widely used in many MR-HIFU applications, including thermal ablation of 
symptomatic uterine leiomyomata. 52, 55, 274 !e main drawback of CEI and the use of contrast agents is 
that the most commonly used compounds are gadolinium-based, which are non-toxic when chelated but 
may dechelate and release the highly toxic gadolinium ion if su&ciently heated. 275, 276 Currently, CEI in 
ablative hyperthermia is limited to post-therapy use for safety reasons.
Magnetic resonance guidance of high-intensity focused ultrasound mediated mild hyperthermia
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Fig. 4.3. MR signal intensity before and after iLTSL injection and heating with MR-HIFU. A) Signal inten-
sity before iLTSL injection. B) Signal intensity after iLTSL injection. C) Example of a temperature elevation 
map during heating. D) Signal intensity after four 10-minute heating sessions. Preferential contrast agent 
release limited to the heated region is evident. A, B, and D depict T1-weighted MR images.
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Di!usion MRI allows in vivo noninvasive mapping of water transport in biological tissues. Water transport 
in tissues is a!ected by tissue structure, and con"ned by macromolecules, "bers, and membranes, 
amongst others. Water molecule di!usion patterns can reveal details about normal and pathological 
tissue architecture. In di!usion-weighted imaging (DWI), each image voxel has a signal intensity that 
re#ects a single best measurement of the local water transport rate. Consequently, DWI is sensitive to 
changes in the di!usion of water molecules in both the intra- and intercellular tissue environments, and 
can be used to assess immediate changes in the tissue structure post-therapy. 265, 277, 278
DWI has been suggested for post-treatment prediction of HIFU-induced cell death, and its use to 
visualize necrotic tissue has been validated in previous studies. 265, 277-279 DWI may also be performed 
during therapy to assess therapy e$ciency, unlike CEI that is limited to post-therapy use. In addition, it 
has been shown that the region of altered di!usion better correlates with the region of thermal damage 
than CEI-based assessment directly a%er HIFU therapy. 277 Disadvantages of DWI include high motion 
sensitivity, as well as long image acquisition times if high spatial resolution, information on directionality 
of transport, or multiple imaging slices are required. 277
Finally, MR elastography can be used to produce images in which contrast is related to relative sti!ness 
of tissue. By applying low frequency sound waves generated by an MRI-compatible acoustic driver, 
tissue sti!ness or elasticity can be imaged by using special phase-contrast MR-imaging sequences. It has 
been previously reported that so% tissue elasticity may be reduced as a result of HIFU-induced thermal 
coagulation and protein denaturation, and that the subsequent reduction in elasticity can be assessed 
using MR elastography. 268, 280 Furthermore, PRFS-based MR thermometry can be performed using data 
acquired for MR elastography, thus allowing for simultaneous evaluation of tissue temperature and 
sti!ness. 269 HIFU exposures also induce shear waves that can then be imaged with MR elastography, 
enabling concurrent production and assessment of MR-HIFU mediated thermal damage while estimating 
the temperature rise with PRFS thermometry. 269, 281, 282 
Chapter 4
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5 Discussion and conclusions
An optimal mild hyperthermia treatment would be spatially accurate, with precise and homogeneous 
heating limited to the target region while also limiting the likelihood of unwanted thermal or mechanical 
bioe!ects. "is places stringent requirements for both the hyperthermia applicator and the mild 
hyperthermia delivery methods. Feedback control of MR-HIFU mediated mild hyperthermia, based 
on the monitored temperature elevation, would be desirable for optimal therapy. Current approaches 
for MR-HIFU mild hyperthermia are limited in number, but focus on the use of PI or PID feedback 
control. 23, 72, 223-225 "ese methods rely in part on tissue parameters, such as local perfusion and 
ultrasound attenuation, which are largely unknown. In addition, these tissue properties are known to 
be spatially heterogeneous and di#cult to measure in vivo, potentially hindering the introduction of 
proportional feedback controllers into clinical work$ow. Publication I demonstrates the development 
and implementation of a binary mild hyperthermia feedback algorithm on a clinical MR-HIFU platform. 
Simplicity of the algorithm makes it an attractive candidate for clinical translation as a similar binary 
feedback method has already been applied in clinical MR-HIFU ablations. 50, 52 
"e requirements placed upon mild hyperthermia heating strategies are very di!erent compared to 
ablative hyperthermia. Desirable properties for ablation include high energy e#ciency of the heating, as 
well as steep temperature gradients for improved lesion delineation. Consequently, steering a single high-
intensity focus along circular trajectories in order to increase the ablation volume has shown bene%t for 
ablation. 51, 52 On the other hand, heating uniformity is of much greater importance for mild hyperthermia, 
and high acoustic pressures resulting from the use of a single focal point may cause rapid, highly localized 
temperature elevations and unwanted mechanical bioe!ects. "us, operating at high acoustic pressures 
presents a potential problem in MR-HIFU mediated mild hyperthermia. Multifoci sonication patterns, 
which distribute the acoustic pressure over a larger area, possibly at the cost of slightly inferior heating 
e#ciency and less well-de%ned treatment borders, may be bene%cial for mild hyperthermia treatments. In 
addition, regulatory implications for MR-HIFU mediated mild hyperthermia may be more favorable for 
low acoustic pressures. Publication II presents the potential bene%ts of a multifoci sonication approach 
combined with a binary feedback algorithm for mild hyperthermia on a clinical MR-HIFU platform. 
Clinical oncology applications that require accurate and precise spatiotemporal control over heating 
(such as chemotherapeutic delivery and radiosensitization) may bene%t from the improved safety and 
heating control o!ered by multifoci MR-HIFU mild hyperthermia.
LTSLs release their drug cargo in response to temperature elevations greater than the melting temperature 
of the lipid formulation. 19, 20 Studies combining LTSLs with local hyperthermia have demonstrated 
significant tumor volume reduction in mouse tumor models compared with conventional free drug or 
non-thermally sensitive liposome therapy. 21, 22, 26, 27 Furthermore, mild hyperthermia has been shown to 
assist drug delivery with liposomes by increasing the sensitivity of cancer cells to chemotherapeutics. 
13 "e combination of regionally targeted, image-guided mild hyperthermia and LTSLs is a clinically 
attractive and potentially feasible strategy for targeted delivery of drug to solid tumors. A variety of 
methods have been developed to achieve local, mild hyperthermia in a solid tumor for combination 
with LTSLs. 27, 283-285 Despite many technological advances, however, current hyperthermia applicators 
are o&en limited in their ability to provide a spatially accurate or deep thermal therapy to a solid tumor. 
To address these challenges, MR-HIFU may be combined with drug-containing LTSLs. "e feasibility of 
combining MR-HIFU with clinical-grade LTSLs in a relevant Vx2 rabbit tumor model is demonstrated 
in publication III. "is drug delivery technique may have potential for clinical translation as an image-
guided method to deliver drug to a solid tumor.
Variability in tumor microenvironment may impact both the heating and delivery of drugs. 28, 29, 153 Direct 
imaging of drug delivery or an appropriate substitute may enable and improve real-time control of drug 
delivery. Co-loading cancer drug and MR contrast agent into LTSLs may provide a suitable substitute 
for quantifying drug delivery using MR-HIFU. LTSLs that release contrast agent from their interior 
have been used to monitor release in vivo, demonstrating correlation of imaging with drug delivery and 
therapeutic e#cacy. 30, 34 Publication IV demonstrates the preparation and characterization of a novel 
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MR imageable liposome formulation (iLTSL) co-loaded with a cancer drug and an MR contrast agent. 
Monitoring of both heating and content release suggest that MR-HIFU mild hyperthermia combined 
with iLTSL may enable real-time spatial control of content release.
A variety of factors, including drug delivery system, drug characteristics, as well as physiological, 
biological, and biophysical parameters, a!ect hyperthermia-mediated drug delivery from LTSLs. 
Computer simulations provide a means to e"ciently examine the e!ects of these parameters. In fact, in 
silico models have provided accurate descriptions of thermal therapies and drug delivery via LTSL and 
other carriers. 286, 287 In publication V, a mathematical model that combines a heat transfer model with 
a drug delivery model to simulate both HIFU-induced tissue heating and hyperthermia-mediated drug 
delivery was validated. #e model can predict temperature distribution and delivered drug concentration 
and may thus allow quantitative comparison of di!erent MR-HIFU heating algorithms as well as facilitate 
therapy planning for this drug delivery technique.
While the abovementioned materials and methods for MR-HIFU mediated mild hyperthermia and 
drug delivery are not yet available for clinical use, MR-HIFU technology is already being utilized in 
the clinic for the ablation of symptomatic uterine leiomyomata as well as for palliative treatment of 
painful osseous metastases. 50, 54-56, 62-64 For clinical translation of MR-HIFU mediated mild hyperthermia 
and drug delivery, it is important to show that current MR-HIFU therapy applications, using novel 
monitoring and control features, are safe and o!er excellent spatial targeting accuracy as well as result 
in a predictable treatment outcome. In publication VI, a clinical MR-HIFU system was utilized for the 
treatment of symptomatic uterine leiomyomata in a phase I clinical trial. #e novel safety and control 
features showcased in this publication may also facilitate the clinical acceptance of MR-HIFU mediated 
mild hyperthermia and drug delivery. 
MR-HIFU mediated mild hyperthermia is an attractive option as a noninvasive hyperthermia therapy 
modality, especially in combination with drug delivery. #e majority of the research for this dissertation 
was targeted at developing and validating materials and methods for safe, robust, and e"cient MR-
HIFU mediated mild hyperthermia and drug delivery for clinical use. #e publications included in this 
dissertation serve as proof-of-principle and highlight the synergistic bene$ts that may be achieved using 
the combination of MR-imaging, HIFU, and LTSLs. However, for this technology to advance into the 
clinic and be used in cancer treatments on a routine basis, further developments may be required. #ese 
developments include large volume conformal MR-HIFU mediated mild hyperthermia, which may 
enable heating the whole tumor in a single therapy session. #is method is currently under development. 
In addition, LTSLs can be designed to target cancerous tissue to further enhance drug delivery to 
tumor and reduce adverse side e!ects. 141 #e concept of using MR-HIFU for clinically relevant mild 
hyperthermia and drug delivery is not just a far-fetched idea, but could very well be realized in the near 
future with some further improvements on the technology and methodology.
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Fulfillment of the objectives
1. !e developed MR-HIFU mild hyperthermia heating algorithm resulted in accurate and 
homogeneous heating within the targeted region in both tissue-mimicking phantoms and in a 
rabbit animal model. (I)
2. A multifoci sonication approach in combination with the mild hyperthermia heating 
algorithm resulted in accurate and precise heating within the targeted region with signi"cantly 
lower acoustic pressures and spatially more con"ned heating, as compared to a single focus 
sonication method. (II)
3. LTSL + MR-HIFU resulted in significantly higher tumor drug concentrations compared to free 
drug and LTSL alone. !is technique may have potential for clinical translation as a method to 
deliver drug to a solid tumor. (III)
4. MR-HIFU enabled monitoring of both heating and content release from a novel MR imageable 
liposome formulation co-loaded with drug and a contrast agent. (IV)
5. A computational model, which can predict temperature distribution and delivered drug 
concentration resulting from combining MR-HIFU with LTSLs, was validated in an in vivo 
study. (V)
In addition, a clinical MR-HIFU system was utilized in publication VI for the treatment of symptomatic 
uterine leiomyomata in a phase I clinical trial, showcasing that this therapy modality is feasible, safe, and 
already in clinical use with impressive targeting accuracy.
Discussion and conclusions
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6 Summary of the publications
Publication I: A binary mild hyperthermia feedback algorithm was developed and implemented 
on a clinical MR-HIFU platform. Sonications resulted in accurate and homogeneous heating within 
the targeted region in both tissue-mimicking phantom and in a rabbit muscle and Vx2 tumor. Mean 
temperatures between 40.4 °C and 41.3 °C with a standard deviation of 1.0–1.5 °C (T10 = 41.7–43.7 °C, T90 
= 39.0–39.6 °C) were measured in vivo, in agreement with in vitro studies. 3D spatial o!set was 0.1–3.2 
mm in vitro and 0.6–4.8 mm in vivo, demonstrating good spatial targeting accuracy. Combination of 
MR-HIFU mild hyperthermia and LTSLs demonstrated heterogeneous delivery to a partially heated Vx2 
tumor. 
Publication II: A multifoci sonication approach was combined with the mild hyperthermia heating 
algorithm developed in publication I, and implemented on a clinical MR-HIFU platform. According to 
both acoustic simulations and hydrophone measurements, the multifoci approach produced signi"cantly 
lower (67% reduction) acoustic peak pressures in the focal region. Combined with the feedback 
algorithm, the multifoci heating method provided robust temperature control, resulting in accurate and 
precise heating within the targeted regions in a tissue-mimicking phantom, in normal rabbit muscle, and 
in a Vx2 tumor. #e multifoci heating approach also resulted in better temperature uniformity in the 
target region and more con"ned heating in the beam path direction compared to the single focus sweep 
sonication method in both simulations and experiments.
Publication III: Clinical-grade LTSLs encapsulating doxorubicin were used with a clinical MR-HIFU 
platform to investigate in vivo image-guided drug delivery. Fi$een rabbits with Vx2 tumors within 
superficial thigh muscle were randomly assigned into three treatment groups of free doxorubicin, 
LTSL, and LTSL+MR-HIFU. Using a clinical MR-HIFU system and the heating algorithm developed 
in publication I, sonication of Vx2 tumors resulted in accurate (mean = 40.5±0.1 °C) and spatially 
homogenous (SD = 1.0 °C) temperature control in the target region. LTSL+MR-HIFU resulted in 
significantly higher tumor drug concentrations compared to free drug (7.6-fold increase) and LTSL alone 
(3.4-fold increase), despite heating only part of the tumor. Feasibility of combining MR-HIFU mediated 
mild hyperthermia with a clinical-grade LTSL in a relevant Vx2 rabbit tumor model was demonstrated.
Publication IV: A novel MR-imageable liposome formulation co-loaded with an MRI contrast agent 
and doxorubicin was developed, and its release at mild hyperthermic temperatures was characterized. 
Release with MR-HIFU was examined in tissue-mimicking phantoms and in a Vx2 rabbit tumor model. 
iLTSL demonstrated consistent size and doxorubicin release kinetics a$er storage at 4 °C for 7 days. 
Release of doxorubicin and contrast agent from iLTSL was minimal at 37 °C but fast when heated to over 
41 °C. Relaxivity of iLTSL increased signi"cantly (from 1.95±0.05 to 4.0±0.1 mMs-1) when heated above 
the phase transition temperature. Signal increase corresponded spatially and temporally to MR-HIFU-
heated locations both in phantoms and in vivo. MR-HIFU enabled monitoring of content release as well 
as control and monitoring of heating.
Publication V: A computational model that simulates MR-HIFU mediated heating of tissue as well 
as the resulting hyperthermia-mediated drug delivery from LTSLs was developed, and validated in 
vivo using a clinical MR-HIFU system and the heating algorithm developed in publication I. MR-
HIFU heating in tissue was simulated using a heat transfer model based on the bioheat equation. A 
spatiotemporal multicompartment pharmacokinetic model simulated intravascular release of drug from 
LTSL, its transport into interstitium, and cell uptake. Mild hyperthermia produced a de"ned region 
of high drug concentration in the target region both in silico and in vivo. In silico, cellular drug uptake 
was directly related to hyperthermia duration, with increasing uptake up to 2 h. Within the heated 
region, temperature di!erence between the model and the experiment was on average 0.54 °C, and the 
doxorubicin concentration pro"le predicted by the model agreed qualitatively with the distribution of 
doxorubicin %uorescence in vivo.
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Publication VI: A clinical MR-HIFU system was utilized for the treatment of symptomatic uterine 
leiomyomata in a phase I clinical trial, as a preliminary investigation into the safety and targeting accuracy 
of the treatment. Adverse events, imaging findings, targeting accuracy, and pathologic evidence of ablation 
were assessed. Eleven women underwent MR-HIFU ablation followed by hysterectomy within 30 days 
of treatment. No serious adverse events were observed, and histopathological assessment as well as MR 
imaging revealed that all leiomyomata were ablated in the planned location. No significant di!erences 
were observed in ablation volume size between MR imaging and histopathology. Mean misregistration 
values were 0.8±1.2 mm in feet-head direction, 0.1±1.0 mm in le"-right direction, and 0.7±3.1 mm along 
the beam axis. Safe and accurate ablation of uterine leiomyomata was achieved using MR-HIFU.
Summary of publications
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